SCHEMBL1303073

SCHEMBL1303073

COc1ccc(C#N)cc1B(O)O

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AR P10275 3/20 0.49
ENPP2 Q13822 3/20 0.47
TUBB4A P04350 3/20 0.45
TUBB P07437 3/20 0.45
TUBA3C P0DPH7 3/20 0.45
TUBA1B P68363 3/20 0.45
TUBA4A P68366 3/20 0.45
TUBB4B P68371 3/20 0.45
TUBB3 Q13509 3/20 0.45
TUBB2A Q13885 3/20 0.45
TUBB8 Q3ZCM7 3/20 0.45
TUBA3E Q6PEY2 3/20 0.45
TUBA1A Q71U36 3/20 0.45
TUBA1C Q9BQE3 3/20 0.45
TUBB6 Q9BUF5 3/20 0.45
TUBB2B Q9BVA1 3/20 0.45
TUBB1 Q9H4B7 3/20 0.45
KDM1A O60341 1/20 0.41
ORAI1 Q96D31 1/20 0.41
ORAI2 Q96SN7 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15010996 0.85 AR (0.51) ARENPP2TUBB4ATUBBTUBA3C
SCHEMBL29954436 0.85 AR (0.51) ARENPP2TUBB4ATUBBTUBA3C
SCHEMBL29956208 0.82 XDH (0.40) ARENPP2TUBB4ATUBBTUBA3C
SCHEMBL29951062 0.80 PNMT (0.39) ARENPP2
SCHEMBL31019037 0.79 AR (0.53) ARENPP2KDM1AALDH1A1USP2
SCHEMBL31750257 0.78 HRH3 (0.44) ENPP2
SCHEMBL509522 0.78 AR (0.66) ARKDM1AALDH1A1USP2KDM4E
SCHEMBL29490258 0.78 AR (0.66) ARKDM1AALDH1A1USP2KDM4E
SCHEMBL388024 0.77 AR (0.51) ARTUBB4ATUBBTUBA3CTUBA1B
SCHEMBL11616908 0.76 KDM1A (0.56) ARKDM1AALDH1A1USP2KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 139 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120118071-A Quinazoline compound and application thereof 北京化工大学 2025-06-10 CN claimed
CN-119751364-A Dimethoxy quinazoline compound and application thereof 中日友好医院(中日友好临床医学研究所) 2025-04-04 CN claimed
US-20260138991-A1 SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES MOMA THERAPEUTICS INC (US) 2026-05-21 US disclosed
EP-4705298-A2 SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES Moma Therapeutics, Inc. (US) 2026-03-11 EP disclosed
EP-4703359-A1 IMIDAZOPYRIDINE OR IMIDAZOPYRAZINE COMPOUND, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION AND USE THEREOF Shanghai Simr Biotechnology Co., Ltd. (CN) 2026-03-04 EP disclosed
US-12559508-B2 Semi-saturated bicyclic derivatives and related uses MOMA THERAPEUTICS, INC. (US) 2026-02-24 US disclosed
US-20260049074-A1 THIADIAZOLYL DERIVATIVES IDEAYA BIOSCIENCES, INC. (US) 2026-02-19 US disclosed
EP-4688772-A1 BIARYL DERIVATIVES AND RELATED USES Moma Therapeutics, Inc. (US) 2026-02-11 EP disclosed
US-20260022114-A1 N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (1,3-THIAZOLYL)](SUBSTITUTED)CARBOXAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING THE AMIDE COMPOUNDS AND OF THEIR USE GILEAD SCIENCES, INC. 2026-01-22 US disclosed
US-20260015360-A1 BIARYL DERIVATIVES AND RELATED USES MOMA THERAPEUTICS, INC. 2026-01-15 US disclosed
US-12509454-B2 Thiadiazolyl derivatives IDEAYA BIOSCIENCES, INC. (US) 2025-12-30 US disclosed
US-7232821-B2 (2-((2-alkoxy)-phenyl) -cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives GLAXO GROUP LIMITED (GB) 2007-06-19 US disclosed
EP-1751114-A2 FACTOR VIIA INHIBITOR PHARMACYCLICS, INC. (US) 2007-02-14 EP disclosed
US-20060205942-A1 e.g. 2-{2-[545-carbamimidoyl-1H-benzoimidazol-2-yl)-6,2'-dihydroxy-5'-sulthmoyl-biphenyl-3-yl]-acetylsmino}-succinamic; anticoagulant, anticarcinogenic, antiinflammatory agent; deep vein thrombosis, rheumatoid arthritis, stroke PHARMACYCLICS LLC 2006-09-14 US disclosed
WO-2005121102-A2 FACTOR VIIA INHIBITOR PHARMACYCLICS, INC. (US) 2005-12-22 WO disclosed
US-20050239802-A1 (2-((2-alkoxy)-phenyl)-cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives GLAXO GROUP LIMITED (GB) 2005-10-27 US disclosed
EP-1569912-A2 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2005-09-07 EP disclosed
EP-1492757-A1 (2-((2-ALKOXY)-PHENYL)-CYCLOPENT-1-ENYL) AROMATIC CARBO- AND HETEROCYCLIC CARBOXYLIC ACID AND DERIVATIVES GLAXO GROUP LIMITED (GB) 2005-01-05 EP disclosed
WO-2004050637-A2 2-(2-HYDROXYBIPHENYL-3-YL)-1H-BENZOIMIDAZOLE-5-CARBOXAMIDINE DERIVATIVES AS FACTOR VIIA INHIBITORS AXYS PHARMACEUTICALS, INC. (US) 2004-06-17 WO disclosed
WO-2003084917-A1 (2-((2-ALKOXY) -PHENYL) -CYCLOPENT-1-ENYL) AROMATIC CARBO AND HETEROCYCLIC ACID AND DERIVATIVES GLAXO GROUP LIMITED (GB) 2003-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260049074-A1 THIADIAZOLYL DERIVATIVES POLH, POLM, POLD1 AR 710/4885ENPP2 3365/4885TUBB4A 1731/4885
US-20260022114-A1 N-(5-SUBSTITUTED-[(1,3,4-THIADIAZOLYL) OR (1,3-THIAZOLYL)](SUBSTITUTED)CARBOXAMIDE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF PREPARING THE AMIDE COMPOUNDS AND OF THEIR USE POLK, POLQ, POLB AR 3765/4885ENPP2 2963/4885TUBB4A 977/4885
US-20050239802-A1 (2-((2-alkoxy)-phenyl)-cyclopent-1enyl) aromatic carbo and heterocyclic acid and derivatives CYP2C9, CYP2C19, CNR1 AR 351/4885ENPP2 1174/4885TUBB4A 3294/4885
US-20260015360-A1 BIARYL DERIVATIVES AND RELATED USES POLB, POLA1, POLN AR 526/4885ENPP2 3393/4885TUBB4A 747/4885
US-20260138991-A1 SEMI-SATURATED BICYCLIC DERIVATIVES AND RELATED USES POLA1, SUB1, CTDSP1 AR 1876/4885ENPP2 1684/4885TUBB4A 1983/4885
US-20060205942-A1 e.g. 2-{2-[545-carbamimidoyl-1H-benzoimidazol-2-yl)-6,2'-dihydroxy-5'-sulthmoyl-biphenyl-3-yl]-acetylsmino}-succinamic; anticoagulant, anticarcinogenic, antiinflammatory agent; deep vein thrombosis, rheumatoid arthritis, stroke F7, F9, F5 AR 3854/4885ENPP2 351/4885TUBB4A 3992/4885
US-12559508-B2 Semi-saturated bicyclic derivatives and related uses POLA1, CTDSP1, SUB1 AR 1281/4885ENPP2 2108/4885TUBB4A 1476/4885
US-12509454-B2 Thiadiazolyl derivatives POLD1, POLQ, DNA2 AR 3257/4885ENPP2 3376/4885TUBB4A 1505/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.